

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PAT1118890

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
VELOXIS PHARMACEUTICALS A/S	12/30/2020
RECEIVING PARTY DATA	
Company Name:	VELOXIS PHARMACEUTICALS INC.
Street Address:	1001 WINSTEAD DRIVE, SUITE 310
City:	CARY
State/Country:	NORTH CAROLINA
Postal Code:	27513
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	14140791
Application Number:	17444402
CORRESPONDENCE DATA	
Fax Number:	9173323773
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2128855000
Email:	patents@blankrome.com,judy.yeddo@blankrome.com
Correspondent Name:	Jay P Lessler
Address Line 1:	1271 Avenue of the Americas, 15th Floor
Address Line 4:	New York, NEW YORK 10020
ATTORNEY DOCKET NUMBER:	134391-00330
NAME OF SUBMITTER:	Judy Yeddo
SIGNATURE:	Judy Yeddo
DATE SIGNED:	03/25/2024
Total Attachments: 23	
source=Assignment_5#page1.tif	
source=Assignment_5#page2.tif	
source=Assignment_5#page3.tif	
source=Assignment_5#page4.tif	
source=Assignment_5#page5.tif	

source=Assignment_5#page6.tif
source=Assignment_5#page7.tif
source=Assignment_5#page8.tif
source=Assignment_5#page9.tif
source=Assignment_5#page10.tif
source=Assignment_5#page11.tif
source=Assignment_5#page12.tif
source=Assignment_5#page13.tif
source=Assignment_5#page14.tif
source=Assignment_5#page15.tif
source=Assignment_5#page16.tif
source=Assignment_5#page17.tif
source=Assignment_5#page18.tif
source=Assignment_5#page19.tif
source=Assignment_5#page20.tif
source=Assignment_5#page21.tif
source=Assignment_5#page22.tif
source=Assignment_5#page23.tif

VELOXIS PHARMACEUTICALS A/S

(ASSIGNOR)

AND

VELOXIS PHARMACEUTICALS, INC.

(ASSIGNEE)

**INTELLECTUAL PROPERTY TRANSFER
AGREEMENT**

JANUARY 1, 2021

INTELLECTUAL PROPERTY TRANSFER AGREEMENT (THE "AGREEMENT")

This Agreement is entered into as of January 1, 2021 (the "**Effective Date**")

BETWEEN:

(1) **Veloxis Pharmaceuticals A/S**, a limited liability company duly organized and validly existing under the laws of Denmark with a current address of c/o Bech-Bruun, Langelinie Allé 35, 2100 Copenhagen, Denmark ("**Assignor**"); and

(2) **Veloxis Pharmaceuticals Inc.**, a corporation organized and validly existing under the laws of Delaware with a current address of 1001 Winstead Drive, Suite 310, Cary, North Carolina 27513 ("**Assignee**").

The Assignor and the Assignee are hereinafter individually referred to each as a "**Party**" and jointly as the "**Parties**".

WHEREAS:

- (A) The Assignor conducts the Business (as defined in Appendix 1) is the owner of the Business Intellectual Property (as defined in Appendix 1).
- (B) The Assignee now wishes to accept and take ownership from the Assignor, and the Assignor now wishes to transfer and assign to the Assignee, through a contribution in kind, the Business IP Assets (as defined in Section 1.1) upon the terms and conditions herein.
- (C) Except as otherwise expressly provided or unless the context clearly requires otherwise, capitalized terms shall have the meaning given to them in Appendix 1.

1 Assignment

1.1 The Assignor, through a contribution in kind, hereby transfers and assigns to the Assignee, who hereby accepts and takes ownership, its entire right, title and interest in and to the following assets (collectively, the "**Business IP Assets**") (the "**Assignment**"):

(a) the Business Intellectual Property including the goodwill of the business connected thereto;

(b) the books and records owned by the Assignor in whatever form relating to Business Intellectual Property or on which any of the Business Intellectual Property is recorded (including, without limitation, original trademark registration and renewal certificates);

(c) the Assigned Contracts (as hereinafter defined);

(d) all data, artwork and designs relating to the Business Intellectual Property in whatever medium (e.g., audio, visual and print); and

(e) all rights and claims (whether known or unknown, matured or unmatured, contingent or accrued) against third parties resulting from, arising out of or otherwise with respect to any of the Business Intellectual Property and all remedies related thereto.

- 1.2 The Assignee will effect the Assignment through an in-kind contribution of the Business IP Assets, initially valued by the parties hereto at USD \$881 million, which amount may be adjusted as agreed in writing by the parties at a later date following an updated valuation of the Business IP Assets contemplated by the parties.

2 Further Assurances

- 2.1 The Assignor shall take such actions as are required in order to effect the proper transfer of the right, title and interest in and to the Business IP Assets to the Assignee, including, upon the request by the Assignee, give all consents, execute and deliver all such documents, forms and authorizations as may be necessary or desirable to perfect the Assignee's right in the Business IP Assets, including but not limited to documents, forms and authorizations necessary or desirable to record the transfer with any relevant registration authority.
- 2.2 The Assignor will (1) deliver to the Assignee on request all certificates, title documents and records which are in their possession relating to the Business IP Assets; and (2) provide to the Assignee all other documents or information that the Assignee reasonably requests in relation to the Business IP Assets.
- 2.3 The Assignor will not challenge or oppose, or assist a person to challenge or oppose, Assignee's ownership of, rights in and use of the Business Intellectual Property and any application or registration for the Business Intellectual Property.

3 Amendments

- 3.1 This Agreement can only be amended, changed or modified by an instrument in writing duly executed by the Parties.

4 Counterparts

- 4.1 This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original but all of which


taken together shall constitute one and the same agreement.


5 Governing Law

5.1 This Agreement is governed by the laws of the United States and the state of Delaware.

VELOXIS PHARMACEUTICALS A/S

VELOXIS PHARMACEUTICALS, INC.

By: 

By: 

Name: Masaya Etoh

Name: Craig A. Collard

Title: Director

Title: CEO

Date: 30 December 2020

Date: 28 December 2020

By: 

Name: Daisuke Matsuo

Title: Director

Date: 30 December 2020

**Appendix 1
(Defined Terms)**

"Assigned Contracts"	means all contracts, including coexistence agreements and consents, all assignments, licenses and license agreements (including all rights therein), including but not limited to patent and trademark licenses to which Assignor is a party (by having entered into, assigned, or otherwise acquired right to such contract), related to or in connection with the Business Intellectual Property;
"Business"	means the research, development, production, distribution, advertising, marketing and sale of pharmaceuticals by Assignor and its subsidiaries and affiliates;
"Business Intellectual Property"	means all the intellectual property owned by and licensed to the Assignor (including, in particular and without limitation all intellectual property related to the Assignor's brands, such as those brands and trademarks set forth in Appendix 3), including, without limitation, all Trademarks; Patents; domain names; rights in designs; copyrights; and trade secrets; whether or not registered and including applications for registration of any such right, and all rights or forms of protection of a similar nature or having equivalent or similar effect which may subsist anywhere in the world;
"Patents"	all inventions and discoveries (whether or not patentable and whether or not reduced to practice), improvements thereto, and patents, patent applications, patent disclosures, invention disclosures, and any renewals, revisions, reissues, divisions and divisionals thereof, applications and patents claiming priority therefrom including, without limitation, the patent registrations and applications listed in <u>Appendix 2</u> , and the right to claim priority from all such applications and patents;
"Territory"	means worldwide; and
"Trademarks"	means all trademarks, service marks, trade names, business names, trade dress, logos, and slogans owned by the Assignor and used or intended for use in the operation of the Business, whether or not registered, and any applications therefor, together with the goodwill of the business connected thereto, including, without limitation, the right to sue for past, present and future infringement, and including, without limitation, the trademark registrations and applications listed in <u>Appendix 3</u> .

**Appendix 2
(Patents)**

Jurisdiction	Patent #	Application #	Filing Date	Issue/Grant Date	Priority Date	Title
USA - (US)	9173847	11/449918	06/09/2006	11/03/2015		TABLET COMPRISING A FIBRATE
US - (United States)	7217431	10/482558	07/26/2004	05/15/2007		Controlled Agglomeration
USA - (US)	7217431	10/482558	07/26/2004	05/15/2007		Controlled Agglomeration
USA - (US)	8535799	11/711965	02/27/2007	09/17/2013		Controlled Agglomeration
USA - (US)	8,591,946	10/569,862	06/13/2006	11/26/2013		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	7994214	10/569863	06/13/2006	08/09/2011		Solid dispersions comprising tacrolimus
USA - (US)	7252247	10/519992	01/04/2005	08/07/2007		Self-Cleaning Spray Nozzle
USA - (US)	7658944	10/513807	11/08/2004	02/09/2010		Solid Dosage Form Comprising A Fibrate
USA - (US)	8124125	12/642563	12/18/2009	02/28/2012		SOLID DOSAGE FORM COMPRISING A FIBRATE
USA - (US)	8685998	12/499034	07/07/2009	04/01/2014		Tacrolimus For Improved Treatment Of Transplant Patients
USA - (US)	9549918	13/029304	02/17/2011	01/24/2017		STABILIZED TACROLIMUS COMPOSITION
USA - (US)	8,617,599	13/167095	06/23/2011	12/31/2013		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	8,623,410	13/167160	06/23/2011	01/07/2014		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	8,586,084	13/167,281	06/23/2011	11/19/2013		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	8,623,411	13/167,334	06/23/2011	01/07/2014		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	8664239	13/167420	06/23/2011	03/04/2014		TACROLIMUS FOR IMPROVED

						TREATMENT OF TRANSPLANT PATIENTS
USA - (US)	8486993	13/178280	07/07/2011	07/16/2013		SOLID DISPERSIONS COMPRISING TACROLIMUS
USA - (US)	8481078	13/315030	12/08/2011	07/09/2013		SOLID DOSAGE FORM COMPRISING A FIBRATE
USA - (US)	9295653	13/969300	08/16/2013	03/29/2016		Controlled Agglomeration
USA - (US)	8889185	14/079414	11/13/2013	11/18/2014		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	9161907	14/079443	11/13/2013	10/20/2015		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	8889186	14/079466	11/13/2013	11/18/2014		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	9168246	14/317500	06/27/2014	10/27/2015		IMPROVED REGIMEN FOR SUPPRESSING ORGAN REJECTION
USA - (US)		14/635,950	03/02/2015			Porous Tablets As Carriers For Liquid Formulations
USA - (US)	9,775,834	14/867,773	09/28/2015	10/03/2017		REGIMEN FOR SUPPRESSING ORGAN REJECTION
USA - (US)	9,757,362	14/855,624	09/16/2015	09/12/2017		MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	9,763,920	14/934,908	11/06/2015	09/19/2017		SOLID DISPERSIONS COMPRISING TACROLIMUS
USA - (US)	10,864,199	15/041,986	02/11/2016	12/15/2020		TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS
EP - (European Patent Convention)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
EPC - (EP)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
EP - (European Patent Convention)	2347756	10186171.4	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
EPC - (EP)	2347756	10186171.4	07/05/2002	5/8/2019		CONTROLLED AGGLOMERATION

Brazil - (BR)	PI 0414000-1	PI0414000-1	08/30/2004	11/5/2029		PHARMACEUTICAL COMPOSITION SOLID, DOSAGE FORM, USE OF THE PHARMACEUTICAL COMPOSITION, AND, METHOD FOR THE PREPARATION OF COMPOSITION
Brazil - (BR)	PI 0413927-5	PI0413927-5	08/30/2004	11/12/2029		PHARMACEUTICAL COMPOSITION SOLID, DOSAGE FORM, USE OF THE PHARMACEUTICAL COMPOSITION, AND, METHOD FOR THE PREPARATION OF COMPOSITION
Norway - (NO)	337869	20061430	08/30/2004	07/04/2016		SOLID DISPERSIONS COMPRISING TACROLIMUS
Canada - (CA)	2688381	2688381	05/30/2008	10/11/2016		ONCE DAILY ORAL DOSAGE FORM COMPRISING TACROLIMUS
EP - (European Patent Convention)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FORM COMPRISING TACROLIMUS
EPC - (EP)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FORM COMPRISING TACROLIMUS
Canada - (CA)		2,729,948	07/07/2009			TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS
South Korea - (KR)	10- 1714090	10-2011- 7002996	07/07/2009	03/02/2017		TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS
EP - (European Patent Convention)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
EPC - (EP)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Eurasian Patent Convention - (EA)	027869	201390412	02/17/2011	09/29/2017		Stabilized tacrolimus composition
Argentina - (AR)	P11010048 3	AR2011P1004 83	02/17/2011	02/17/2011		Stabilized tacrolimus composition
Argentina - (AR)		P20110100483	02/17/2011	02/17/2031		STABILIZED TACROLIMUS

						COMPOSITION
EP - (European Patent Convention)	1680091	04762887.0	10/01/2004	05/31/2017		A SOLID DOSAGE FORM COMPRISING A FIBRATE
EPC - (EP)	1680091	04762887.0	10/01/2004	05/31/2017		A SOLID DOSAGE FORM COMPRISING A FIBRATE
USA - (US)	10,166,190	15/405,879	01/13/2017	01/01/19		STABILIZED TACROLIMUS COMPOSITION
USA - (US)		15/677,938	08/15/2017			MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS
USA - (US)	10,548,880	15/676,727	08/14/2017	06/13/2026		SOLID DISPERSIONS COMPRISING TACROLIMUS
USA - (US)	10,485,793	15/682,275	08/21/2017	6/27/2034		REGIMEN FOR SUPPRESSING ORGAN REJECTION
CA - (Canada)	2,540,984	2,540,984	10/01/2004	02/08/2011		A SOLID DOSAGE FORM COMPRISING A FIBRATE
Canada - (CA)	2540984	2540984	10/1/2004	2/8/2011		A SOLID DOSAGE FORM COMPRISING A FIBRATE
CA - (Canada)	2,452,330	2,452,330	07/05/2002	03/22/2011		CONTROLLED AGGLOMERATION
Canada - (CA)	2452330	2452330	7/5/2002	3/22/2011		CONTROLLED AGGLOMERATION
CA - (Canada)	2,511,150	2,511,150	12/22/2003	07/06/2010		A SELF-CLEANING SPRAY NOZZLE
Canada - (CA)	2511150	2511150	12/22/2003	7/6/2010		A SELF-CLEANING SPRAY NOZZLE
Australia - (AU)	2004267910	2004267910	03/17/2006	03/17/2026		Solid dispersions comprising tacrolimus
Australia - (AU)	2004267909	2004267909	03/17/2006	03/17/2026		Modified Release Compositions Comprising Tacrolimus
Australia - (AU)	2005256322	2005256322	12/12/2006	12/12/2026		Porous Tablets As Carriers For Liquid Formulations
Australia	2002325192	2002325192	12/24/2003	09/08/2008		Controlled Agglomeration I
Austria	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Austria	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Austria	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Azerbaijan	27869	201390412	2/17/2011	09/22/2017		STABILIZED TACROLIMUS COMPOSITION
Belgium	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle

Belgium	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Belgium	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
BG - (Bulgaria)	1663216	04762794.8	03/16/2006	11/02/2011		Modified Release Compositions Comprising Tacrolimus
Bulgaria	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Bulgaria	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Canada	2537041	2537041	2/24/2006	04/03/2012		COMPOSITIONS A LIBERATION MODIFIEE, A BASE DE TACROLIMUS
Canada	2537044	2537044	2/24/2006	04/17/2012		SOLID DISPERSIONS COMPRISING TACROLIMUS
Canada	2572180	2572180	12/27/2006	05/20/2014		POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS
Canada	2634160	2634160	6/18/2008	04/15/2014		DISINTEGRATING LOADABLE TABLETS
China	200480028334.4	200480028334.4	3/29/2006	04/06/2011		Tacrolimus
China	200480029600.5	200480029600.5	4/10/2006	10/21/2009		Fenofibrate I
China	200380106879.8	200380106879.8	6/20/2005	09/03/2008		Self-Cleaning Nozzle
China	2813654.3	2813654.3	2/13/2004	01/13/2010		Controlled Agglomeration I
China	200580024910.2	200580024910.2	1/23/2007	09/29/2010		Porous Tablet
China	200780001882.1	200780001882.1	7/3/2008	08/29/2012		Disintegrating Tablets
Czech Republic	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Czech Republic	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Denmark	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Denmark	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Denmark	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Denmark	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Estonia	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Europe	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Europe	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Europe	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Finland	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Finland	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
France	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
France	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
France	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
France	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Germany	60306760.3	03767489.2	12/12/2004	07/12/2006		Self-Cleaning Nozzle
Germany	602004028	04762795.5	3/16/2006	07/10/2010		Tacrolimus

	023.2					
Germany	602004035 143.1	04762794.8	3/16/2006	07/07/2010		Tacrolimus
Germany	602007014 810.3	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Germany	602011027 417.1	11704177.2	11/14/2012	05/13/2016		Stabilized Tacrolimus
Germany	602008049 841.7	08748829.2	12/29/2009	03/17/2007		Tacro Once Daily Oral Dosage
Great Britain	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Great Britain	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Great Britain	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Great Britain	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Greece	3072860	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Greece	3077124	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Greece	3090023	11704177.2	11/14/2012	05/13/2016		Stabilized Tacrolimus
Hong Kong	1096032	07103423.4	3/16/2006	09/02/2011		Tacrolimus
Hong Kong	1096034	07103452.8	3/30/2007	10/21/2009		Fenofibrate I
Hungary	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Hungary	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Hungary	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
India	221724	2506/DELNP/2 005	6/9/2005	07/03/2008		Self-Cleaning Nozzle
India	242657	00025/DELNP/ 2004	1/2/2004	09/03/2010		Controlled Agglomeration I
India	234120	1058/CHENP/2 006	2/28/2006	06/5/2009		Tacrolimus
India	234522	1049/CHENP/2 006	2/28/2006	06/04/2009		Tacrolimus
IN - (India)		7706/DELNP/2 006	12/19/2006			"POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS"
Ireland	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Ireland	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Ireland	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Ireland	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Italy	502016000 091869	11704177.2	11/14/2012	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Italy	502010901 876440	04762795.5	8/30/2004	07/07/2010		Tacrolimus
Italy	502012902 018684	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Italy	502017000 080755	08748829.22	12/29/2009	05/12/2014		Tacro Once Daily Oral Dosage
Japan	4996249	2006-524226	8/30/2004	05/18/2012		Tacrolimus
Japan	4903568	2006-524227	2/27/2005	01/13/2012		Tacrolimus
Japan	5069001	2006-529648	4/6/2006	08/24/2012		Fenofibrate I
Japan	5403912	2007-518451	12/27/2006	11/08/2013		Porous Tablet

Japan	5498020	2008-548932	7/3/2008	03/14/2014		Disintegrating Tablets
Japan		2011-150025	7/6/2011			
Japan	4570357	2003-510012	12/26/2003	08/20/2010		Controlled Agglomeration I
Japan	4330539	2004-561101	6/16/2005	06/29/2009		Self-Cleaning Nozzle
Kazakhstan	27869	201390412	2/17/2011	09/29/2017		STABILIZED TACROLIMUS COMPOSITION
Luxembourg	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Luxembourg	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Luxembourg	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Luxembourg	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Mexico	295085	PA/a/2006/002247	2/27/2006	01/23/2012		Tacrolimus
Mexico	281035	PA/a/2006/002246	2/27/2006	11/17/2010		Tacrolimus
Mexico	303608	PA/A/2006/014894	12/18/2006	09/21/2012		Porous Tablet
Mexico	290507	MX/a/2008/008662	7/2/2008	09/27/2011		Disintegrating Tablets
Monaco	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Monaco	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Netherlands	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Netherlands	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Netherlands	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Netherlands	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Norway	334986	20061429	3/29/2006	08/18/2014		Tacrolimus
Poland	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Poland	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Portugal	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Portugal	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Romania	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Romania	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Russia	27869	201390412	2/17/2011	09/29/2017		STABILIZED TACROLIMUS COMPOSITION
Russia	2330642	2004103462	7/5/2002	08/10/2008		Controlled Agglomeration I
Russia	2574006	2011104205	2/8/2011	01/27/2016		Tacro in Transplant Treatment
Russia	13632	200700173	1/26/2007	06/30/2010		Porous Tablet
Russia	18606	200870149	8/4/2008	09/30/2013		Disintegrating Tablets
Serbia	P-2016/0748	11704177.2	2/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Slovakia	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Slovakia	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Slovenia	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Slovenia	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus

South Africa	2004/0004 4	2004/00044	1/5/2004			Controlled Agglomeration I
South Korea	1352299	2007-7000836	1/12/2007	01/09/2014		Porous Tablet
South Korea	1486590	10-2008- 7019158	8/4/2008	01/20/2015		Disintegrating Tablets
Spain	149703	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Spain	1663217	04762795.5	3/16/2006	07/10/2010		Tacrolimus
Spain	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Sweden	1663217	04762795.5	3/16/2006	07/10/2010		Tacrolimus
Sweden	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Sweden	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Switzerland	1497034	03767489.2	11/12/2004	07/12/2006		Self-Cleaning Nozzle
Switzerland	1663217	04762795.5	3/16/2006	07/07/2010		Tacrolimus
Switzerland	1663216	04762794.8	3/16/2006	11/02/2011		Tacrolimus
Switzerland	1973529	07700149.3	6/13/2008	05/25/2011		Disintegrating Tablets
Taiwan	100105285	100105285	2/17/2011	12/01/2015		Stabilized Tacrolimus
Turkey	1663216	04762794.8		11/02/2011		Tacrolimus
Turkey	1663217	04762795.5		07/07/2010		Tacrolimus
US - (United States)		16/188,805	11/13/2018			STABILIZED TACROLIMUS COMPOSITION
United States - (US)		16/657,368	10/18/2019	08/30/2024		SOLID DISPERSIONS COMPRISING TACROLIMUS
United States - (US)		16/678,527	11/08/2019	06/27/2034		REGIMEN FOR SUPPRESSING ORGAN REJECTION
United States - (US)		17/085,291	10/30/2020			TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS
United States - (US)		17/085,379	10/30/2020			TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS
AT - (Austria)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
DE - (Germany)	1406594	60249922.4	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
ES - (Spain)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
FR - (France)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
GB - (Great Britain)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
IT - (Italy)	1406594	502019000048 759	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
NL - (Netherlands)	1406594	02758174.3	07/05/2002	06/05/2019		CONTROLLED AGGLOMERATION
AT - (Austria)	2347756	10186171.4	07/05/2002	05/08/2019		CONTROLLED

						AGGLOMERATION
DE - (Germany)	2347756	60249898.8	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
ES - (Spain)	2347756	10186171.4	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
FR - (France)	2347756	10186171.4	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
GB - (Great Britain)	2347756	10186171.4	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
IT - (Italy)	2347756	502019000048 780	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
NL - (Netherlands)	2347756	10186171.4	07/05/2002	05/08/2019		CONTROLLED AGGLOMERATION
AT - (Austria)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Austria - (AT)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Belgium - (BE)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Bulgaria - (BG)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
CH - (Switzerland)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Switzerland - (CH)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
CZ - (Czech Republic)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Czech Republic - (CZ)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
DE - (Germany)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Germany - (DE)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING

						TACROLIMUS
Denmark - (DK)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
DK - (Denmark)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Estonia - (EE)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Spain - (ES)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Finland - (FI)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
France - (FR)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Great Britain - (GB)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Greece - (GR)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Hungary - (HU)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Ireland - (IE)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Italy - (IT)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Lithuania	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Lithuania - (LT)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING

						TACROLIMUS
Luxembourg - (LU)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Monaco - (MC)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Netherland - (NL)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Norway - (NO)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Poland - (PL)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Romania - (RO)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Sweden - (SE)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Slovenia - (SI)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Slovak Republic - (SK)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
Turkey - (TR)	2167033	08748829.2	05/30/2008	04/19/2017		ONCE DAILY ORAL DOSAGE FROM COMPRISING TACROLIMUS
AT - (Austria)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Austria - (AT)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Belgium - (BE)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Bulgaria - (BG)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS

						COMPOSITION
CH - (Switzerland)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Switzerland - (CH)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
CZ - (Czech Republic)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Czech Republic - (CZ)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
DE - (Germany)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Germany - (DE)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Denmark - (DK)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
DK - (Denmark)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Estonia - (EE)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Spain - (ES)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Finland - (FI)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
France - (FR)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Great Britain - (GB)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Greece - (GR)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Hungary - (HU)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Ireland - (IE)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Iceland - (IS)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION

Italy - (IT)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Liechtenstein - (LI)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Lithuania	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Lithuania - (LT)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Luxembourg - (LU)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Latvia - (LV)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Monaco - (MC)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Malta - (MT)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Netherland - (NL)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Norway - (NO)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Poland - (PL)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Portugal - (PT)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Romania - (RO)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Serbia- Montenegro - (RS)	2575769	P-2016/0748	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Sweden - (SE)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Slovenia - (SI)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Slovak Republic - (SK)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED TACROLIMUS COMPOSITION
Turkey - (TR)	2575769	11704177.2	02/17/2011	06/15/2016		STABILIZED

						TACROLIMUS COMPOSITION
--	--	--	--	--	--	---------------------------

**Appendix 3
(Trademarks)**

Country	Trademark	Appl. No.	Appl. Date	Reg. No.	Reg. Date	Classes
Denmark	ARTRANS	VA 2011 01993	7/7/2011	VR 2011 02211	9/9/2011	05, 42, 44
EU	ARTRANS	010104982	7/7/2011	010104982	12/8/2011	05, 42, 44
Denmark	ENVARRIO	VA 2012 01778	7/2/2012	VR 2012 02043	8/16/2012	05, 40, 42, 44
EU	ENVARRIO	011135928	8/23/2012	011135928	1/22/2013	05, 40, 42, 44
WIPO Protocol (Madrid)	ENVARRIO	MP 2013 00023	2/7/2013	1 168 260	2/7/2013	05, 40, 42, 44
Albania	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Andorra	ENVARUSUS	27.921	7/22/2013	32.330	7/22/2013	05, 42, 44
Armenia	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Azerbaijan	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Belarus	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Bosnia & Herzegovina	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Canada	ENVARUSUS	1,710,475	1/8/2015	1,035,019	7/3/2019	05, 40, 42, 44
China	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Denmark	ENVARUSUS	VA 2012 01777	7/2/2012	VR 2012 02124	8/27/2012	05, 40, 42, 44
EU	ENVARUSUS	011135894	8/23/2012	011135894	1/22/2013	05, 40, 42, 44
Georgia	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Iceland	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Kazakhstan	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Kyrgyzstan	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Liechtenstein	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Macedonia, The Former Yugoslav Republic of	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Moldova	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Monaco	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Montenegro	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Norway	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Russia	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44

San Marino	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Serbia	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Switzerland	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Tajikistan	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Turkey	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Turkmenistan	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
Ukraine	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
USA	ENVARUSUS		2/7/2013	1 168 212	2/7/2013	05, 40, 42, 44
Uzbekistan	ENVARUSUS		7/15/2013	1 168 212	2/7/2013	05, 42, 44
WIPO Protocol (Madrid)	ENVARUSUS	MP 2013 00022	2/7/2013	1 168 212	2/7/2013	05, 40, 42, 44
China	ENVARUSUS (Chinese characters)	13043282	8/7/2013	13043282	1/7/2015	05
China	ENVARUSUS (Chinese characters)	13043279	8/7/2013	13043279	12/28/2014	44
China	ENVARUSUS (Chinese characters)	13043280	8/7/2013	13043280	4/21/2015	42
Hong Kong	ENVARUSUS (Chinese characters)	302913020	3/4/2014	302913020	3/4/2014	05, 42, 44
Taiwan	ENVARUSUS (Chinese characters)	103017027	3/28/2014	1691540	2/1/2015	05, 42, 44
Belarus	ENVARUSUS (Cyrillic Letters)		8/15/2013	1 179 846	8/15/2013	05, 42, 44
Bulgaria	ENVARUSUS (Cyrillic Letters)		8/15/2013	1 179 846	8/15/2013	05, 42, 44
Denmark	ENVARUSUS (Cyrillic Letters)	VA 2013 01860	7/17/2013	VR 2013 01708	7/23/2013	05, 42, 44
Macedonia, The Former Yugoslav Republic of	ENVARUSUS (Cyrillic Letters)		8/15/2013	1 179 846	8/15/2013	05, 42, 44
Russia	ENVARUSUS (Cyrillic Letters)		8/15/2013	1 179 846	8/15/2013	05, 42, 44
Ukraine	ENVARUSUS (Cyrillic Letters)		8/15/2013	1 179 846	8/15/2013	05, 42, 44
WIPO Protocol (Madrid)	ENVARUSUS (Cyrillic Letters)	MP 2013 00208	8/15/2013	1 179 846	8/15/2013	05, 42, 44
Denmark	Envarus logo (fig in)	VA 2014 01422	6/13/2014	VR 2014 02207	10/13/2014	05, 40, 42, 44

	colours)					
EU	Envarsus logo (fig in colours)		10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
Norway	Envarsus logo (fig in colours)		10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
Russia	Envarsus logo (fig in colours)		10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
Switzerland	Envarsus logo (fig in colours)		10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
Turkey	Envarsus logo (fig in colours)		10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
USA	Envarsus logo (fig in colours)		10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
WIPO Protocol (Madrid)	Envarsus logo (fig in colours)	MP 2014 00297	10/16/2014	1 246 623	10/16/2014	05, 40, 42, 44
USA	ENVARUSUS XR	86/270,008	5/2/2014	4,890,115	1/19/2016	05, 44
Canada	Envarsus XR (fig)	1,710,474	1/8/2015	1,034,983	7/3/2019	05, 40, 42, 44
Denmark	Envarsus XR (fig)	VA 2014 01423	6/13/2014	VR 2014 02208	10/13/2014	05, 40, 42, 44
EU	Envarsus XR (fig)		10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
Norway	Envarsus XR (fig)		10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
Russia	Envarsus XR (fig)		10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
Switzerland	Envarsus XR (fig)		10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
Turkey	Envarsus XR (fig)		10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
USA	Envarsus XR (fig)		10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
WIPO Protocol (Madrid)	Envarsus XR (fig)	MP 2014 00298	10/16/2014	1 246 622	10/16/2015	05, 40, 42, 44
China	FENOGLIDE		8/30/2011	1 091 569	8/30/2011	05
Hong Kong	FENOGLIDE	302021462	9/1/2011	302021462	9/1/2011	05
South Korea	FENOGLIDE		8/30/2011	1 091 569	8/30/2011	05
WIPO Protocol (Madrid)	FENOGLIDE	MP 2011 00255	8/30/2011	1 091 569	8/30/2011	05
Denmark	LIFECYCLE PHARMA	VA 2003 01950	5/15/2003	VR 2003 02449	7/11/2003	05, 40, 41, 42
Canada	MELTDOSE	1,869,290	11/22/2017	TMA1,084,3 16	10/9/2020	05, 42
Denmark	MELTDOSE	VA 2002 03446	8/30/2002	VR 2002 04028	11/22/2002	05, 40, 41, 42

EU	MELTDOSE	003071693	2/26/2003	003071693	9/7/2004	05, 40, 41, 42
USA	MELTDOSE	78/219,715	2/27/2003	2,959,361	6/7/2005	42
USA	MELTDOSE	87/631,924	10/3/2017	5,973,549	1/28/2020	05
Denmark	NEXZORB	VA 2011 01994	7/7/2011	VR 2011 02210	9/9/2011	05, 42, 44
EU	NEXZORB	010105021	7/7/2011	010105021	12/8/2011	05, 42, 44
Denmark	Optacto	VA 2010 03817	12/23/2010	VR 2011 00210	1/19/2011	05, 40, 41, 42
Denmark	VELOXIS PHARMACEUTICALS	VA 2011 01713	6/9/2011	VR 2011 02206	9/9/2011	05, 40, 41, 44
Denmark	VELOXIS PHARMACEUTICALS	VA 2011 01841	6/20/2011	VR 2011 02207	9/9/2011	42, 45
EU	VELOXIS PHARMACEUTICALS		7/7/2011	1 088 877	7/7/2011	05, 40, 41, 42, 44, 45
USA	VELOXIS PHARMACEUTICALS		7/7/2011	1 088 877	7/7/2011	05, 40, 41, 42, 44
WIPO Protocol (Madrid)	VELOXIS PHARMACEUTICALS	MP 2011 00187	7/7/2011	1 088 877	7/7/2011	05, 40, 41, 42, 44, 45
Denmark	Veloxis PHARMACEUTICALS (fig)	VA 2011 01842	6/20/2011	VR 2011 02208	9/9/2011	05, 40, 41, 42, 44, 45
Denmark	Veloxis PHARMACEUTICALS (fig)	VA 2011 01842	6/20/2011	VR 2011 02208	9/9/2011	05, 40, 41, 42, 44, 45
Denmark	Veloxis PHARMACEUTICALS (fig)	VA 2011 01842	6/20/2011	VR 2011 02208	9/9/2011	05, 40, 41, 42, 44, 45
EU	Veloxis PHARMACEUTICALS (fig)		7/7/2011	1 093 252	7/7/2011	05, 40, 41, 42, 44, 45
USA	Veloxis PHARMACEUTICALS (fig)		7/7/2011	1 093 252	7/7/2011	05, 40, 41, 42, 44
WIPO Protocol (Madrid)	Veloxis PHARMACEUTICALS (fig)	MP 2011 00186	7/7/2011	1 093 252	7/7/2011	05, 40, 41, 42, 44, 45
Denmark	ZEMCRO	VA 2011 01995	7/7/2011	VR 2011 02209	9/9/2011	05, 42, 44
EU	ZEMCRO	010105071	7/7/2011	010105071	12/8/2011	05, 42, 44

PATENT

RECORDED: 04/02/2024

REEL: 066893 FRAME: 0270